Evocalcet in patients with primary hyperparathyroidism: an open-label, single-arm, multicenter, 52-week, dose-titration phase III study.

Yasuhiro TakeuchiYuichi NishidaYuichiro KondoYasuo ImanishiSeiji Fukumoto

Published in: Journal of bone and mineral metabolism (2020)

Evocalcet demonstrated long-term effectiveness in reducing serum cCa concentrations and safety without any unexpected drug-related TEAEs in PHPT patients.

Keyphrases

phase iii
end stage renal disease
clinical trial
open label
newly diagnosed
chronic kidney disease
ejection fraction
systematic review
peritoneal dialysis
emergency department
drug induced
study protocol